Neurotherapeutics for non-psychiatric disorders present what may be the greatest field of unmet need in medicine. They have been significantly underdiagnosed and vastly underserved for a number of reasons. Certain neurological disorders, such as peripheral neuropathies, are secondary to other conditions, which overshadow the neuropathy. In addition, CNS conditions are frequently undiagnosed or unrecognized because their symptoms may not cause sufficient concern in the patient or may be confused with those of other conditions by the clinician. As a result, the incidence and prevalence of the CNS diseases and disorders that are not seriously debilitating or fatal are significantly underestimated.
However, this unmet need represents a burgeoning opportunity for a new generation of therapeutics. The range of conditions requiring new treatments vary from minor symptoms to completely debilitating and even fatal diseases such as multiple sclerosis and Parkinsons disease. New understandings of genetics are promising early identification of sufferers for conditions caused by inborn errors of metabolism, and although many of these disorders are rare, and may qualify as "orphan diseases" under current law, many share similar underlying mechanisms, opening the possibility of expanded markets for these new treatments.
Until the 1990s, the vast majority of therapeutics for neurological diseases and disorders were palliative. With the rapidly increasing understanding of the nature of the nervous system, its interactions with muscles and other organs, and the cell biology of nerve cells, newer therapeutics are addressing root causes of neurological problems. Small biopharmaceutical companies are leading the way in advances in modern neurotherapeutics. The number of such companies, focused on neurotherapeutics, has increased significantly in the past five years and may be expected to increase further during the near term.
Kalorama’s new study looks at the worldwide market and market potential for drugs to treat these widely varying, but deadly similar diseases. The report covers the unmet need and commercial outlook for such conditions as:
Brain trauma ans stroke
Spinal cord injuries and diseases
Dementia disorders, such as Alzheimer’s disease
The study reviews current therapeutic approaches as well as forward-looking technologies, such as biological therapy, immunotherapy, and gene therapy. The study also provides a complete competitive and strategic analysis and overview of regulatory and clinical trends.